RY 160.91 0.3555% SHOP 116.03 -0.4718% TD 83.98 0.2148% ENB 62.82 1.4699% BN 68.81 1.6396% TRI 251.78 0.6959% CNQ 39.88 2.0732% CP 103.16 1.9771% CNR 137.31 0.483% BMO 129.32 0.4661% BNS 65.69 0.551% CSU 4682.54 -0.7613% CM 81.6 0.1473% MFC 39.65 -0.0252% ATD 71.3 1.3072% NGT 76.22 -1.6643% TRP 68.46 0.9586% SU 47.8 2.006% WCN 273.36 0.3156% L 213.68 0.1594%
Last update at 2025-04-17T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Fri 18 Apr 25, 09:16 AMMag 7 slide, gold rises, Bausch + Lomb recall: Market Minute
Fri 28 Mar 25, 05:33 PMWhy Bausch + Lomb (BLCO) Shares Are Plunging Today
Fri 28 Mar 25, 05:20 PMWhy Bausch + Lomb (BLCO) Stock Is Nosediving
Thu 27 Mar 25, 06:54 PMBausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
Mon 17 Mar 25, 11:00 AMBausch + Lomb Full Year 2024 Earnings: EPS Misses Expectations
Thu 20 Feb 25, 10:33 AMQ4 2024 Bausch + Lomb Corp Earnings Call
Thu 20 Feb 25, 07:41 AMBausch & Lomb Corp (BLCO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Thu 20 Feb 25, 07:03 AMBausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent
Wed 19 Feb 25, 01:53 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 73.00M | 318.00M | 290.00M | 399.00M | 417.00M |
| Minority interest | -9.00000M | -11.00000M | -1.00000M | -5.00000M | - |
| Net income | 15.00M | 182.00M | -17.00000M | 298.00M | 710.00M |
| Selling general administrative | 1478.00M | 1389.00M | 1253.00M | 1382.00M | - |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2249.00M | 2298.00M | 2127.00M | 2451.00M | 2352.00M |
| Reconciled depreciation | 244.00M | 415.00M | 442.00M | 469.00M | - |
| Ebit | 207.00M | 329.00M | 260.00M | 532.00M | 416.00M |
| Ebitda | 457.00M | 785.00M | 750.00M | 1001.00M | 932.00M |
| Depreciation and amortization | 250.00M | 456.00M | 490.00M | 469.00M | 516.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 207.00M | 329.00M | 260.00M | 532.00M | 416.00M |
| Other operating expenses | 3548.00M | 3419.00M | 3114.00M | 3315.00M | 3238.00M |
| Interest expense | 146.00M | 63.00M | 19.00M | 138.00M | 29.00M |
| Tax provision | 58.00M | 125.00M | 307.00M | 96.00M | - |
| Interest income | 6.00M | 0.00000M | 3.00M | 1.00M | - |
| Net interest income | -140.00000M | 0.00000M | 3.00M | 1.00M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 58.00M | 125.00M | 307.00M | 96.00M | -302.00000M |
| Total revenue | 3768.00M | 3765.00M | 3412.00M | 3778.00M | 3665.00M |
| Total operating expenses | 2029.00M | 1952.00M | 1829.00M | 1988.00M | 1925.00M |
| Cost of revenue | 1519.00M | 1467.00M | 1285.00M | 1327.00M | 1313.00M |
| Total other income expense net | -134.00000M | -11.00000M | 30.00M | -133.00000M | 1.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 15.00M | 193.00M | -17.00000M | 303.00M | - |
| Net income applicable to common shares | 6.00M | 182.00M | -18.00000M | 298.00M | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 13442.00M | 11144.00M | 10823.00M | 11266.00M | 11468.00M |
| Intangible assets | 3589.00M | 2058.00M | 2264.00M | 2562.00M | 2855.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 541.00M | 431.00M | 168.00M | 155.00M | 198.00M |
| Total liab | 6522.00M | 4043.00M | 1421.00M | 1278.00M | 1436.00M |
| Total stockholder equity | 6850.00M | 7033.00M | 9329.00M | 9918.00M | 9959.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 400.00M | 901.00M | 860.00M | 731.00M | 773.00M |
| Common stock | - | - | 10364.00M | 10807.00M | 11005.00M |
| Capital stock | 0.00000M | 0.00000M | 10364.00M | 10807.00M | 11005.00M |
| Retained earnings | -254.00000M | 6.00M | - | - | - |
| Other liab | - | 244.00M | 230.00M | 286.00M | 324.00M |
| Good will | 4575.00M | 4507.00M | 4586.00M | 4685.00M | 4554.00M |
| Other assets | - | 1023.00M | 1001.00M | 1101.00M | 1274.00M |
| Cash | 331.00M | 354.00M | 174.00M | 238.00M | 192.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1579.00M | 1296.00M | 1099.00M | 909.00M | 1035.00M |
| Current deferred revenue | 627.00M | - | - | - | - |
| Net debt | 4231.00M | 2082.00M | -174.00000M | -238.00000M | -192.00000M |
| Short term debt | 30.00M | 25.00M | - | - | - |
| Short long term debt | 30.00M | 25.00M | - | - | - |
| Short long term debt total | 4562.00M | 2436.00M | - | - | - |
| Other stockholder equity | 8349.00M | 8285.00M | -1035.00000M | -889.00000M | -1046.00000M |
| Property plant equipment | - | 1419.00M | 1337.00M | 1264.00M | 1090.00M |
| Total current assets | 2742.00M | 2137.00M | 1635.00M | 1654.00M | 1695.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 468.00M | 2479.00M | 2671.00M | 2550.00M |
| Short term investments | - | - | - | - | - |
| Net receivables | 839.00M | 724.00M | 721.00M | 645.00M | 713.00M |
| Long term debt | 4532.00M | 2411.00M | - | - | - |
| Inventory | 1028.00M | 628.00M | 572.00M | 616.00M | 592.00M |
| Accounts payable | 522.00M | 370.00M | 239.00M | 178.00M | 262.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1245.00000M | -1258.00000M | -1035.00000M | -889.00000M | -1046.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 225.00M | 215.00M | 180.00M | 165.00M | 175.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 10700.00M | 9007.00M | 9188.00M | 9612.00M | 9773.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -215.00000M | -214.00000M | -256.00000M | -186.00000M | - |
| Change to liabilities | 189.00M | 163.00M | -144.00000M | 78.00M | - |
| Total cashflows from investing activities | -215.00000M | -214.00000M | -256.00000M | -186.00000M | - |
| Net borrowings | 2458.00M | 28.00M | 28.00M | 28.00M | - |
| Total cash from financing activities | 81.00M | -712.00000M | -232.00000M | -606.00000M | -665.00000M |
| Change to operating activities | -7.00000M | -13.00000M | 40.00M | -6.00000M | - |
| Net income | 15.00M | 193.00M | -17.00000M | 303.00M | 719.00M |
| Change in cash | 203.00M | -61.00000M | 46.00M | 4.00M | 16.00M |
| Begin period cash flow | 177.00M | 238.00M | 192.00M | 188.00M | 172.00M |
| End period cash flow | 380.00M | 177.00M | 238.00M | 192.00M | 188.00M |
| Total cash from operating activities | 345.00M | 873.00M | 522.00M | 799.00M | 763.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 379.00M | 415.00M | 442.00M | 469.00M | 495.00M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -106.00000M | -15.00000M | -32.00000M | -91.00000M | -7.00000M |
| Change to account receivables | -95.00000M | -107.00000M | 77.00M | -21.00000M | -9.00000M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 94.00M | -712.00000M | -232.00000M | -606.00000M | -665.00000M |
| Change to netincome | -21.00000M | 248.00M | 157.00M | 72.00M | - |
| Capital expenditures | 175.00M | 209.00M | 259.00M | 180.00M | 101.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -19.00000M | 28.00M | -59.00000M | -40.00000M | -78.00000M |
| Stock based compensation | 62.00M | 62.00M | 50.00M | 50.00M | 43.00M |
| Other non cash items | -2.00000M | 59.00M | 9.00M | 56.00M | 28.00M |
| Free cash flow | 170.00M | 664.00M | 263.00M | 619.00M | 662.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb Corp |
0.45 2.77% | 16.68 | - | 17.36 | 2.09 | 1.07 | 2.42 | 20.09 |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph C. Papa | CEO & Director | 1956 |
| Mr. Osama A. Eldessouky | Exec. VP & CFO | 1972 |
| Ms. Christina M. Ackermann | Exec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals | 1965 |
| Mr. Joseph F. Gordon | Pres of Global Consumer, Surgical & Vision Care | 1965 |
| Ms. Kelly Webber | Exec. VP & Chief HR Officer | NA |
| Dr. Yehia Hashad M.D. | Exec. VP of R&D and Chief Medical officer | 1967 |
| Mr. Louis W. Yu | Exec. VP & Chief Quality Officer | 1950 |
| Mr. Dennis Asharin | Exec. VP and Chief Global Manufacturing & Supply Chain Officer | NA |
| Mr. Brenton L. Saunders J.D. | CEO & Chairman | 1970 |
| Mr. Osama A. Eldessouky | Executive VP & CFO | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA
NZ
UK
US
AU
IND
Please wait processing your request...